Revealing the Earliest Signals of Disease in the Plasma Proteome

Revealing the Earliest Signals of Disease in the Plasma Proteome


Our platform connects population-scale plasma proteomics with longitudinal health outcomes to discover molecular signals linked to future disease.

DIAGNOSTIC GAP

Disease biology begins before diagnosis

Many diseases develop silently for years before symptoms appear. Current clinical testing often captures only late-stage biology, missing earlier molecular signals that could support prevention, monitoring and earlier intervention.

Many diseases develop silently for years before symptoms appear. Current clinical testing often captures only late-stage biology, missing earlier molecular signals that could support prevention, monitoring and earlier intervention.

>50%

of cancers are still diagnosed at later stages, when treatment options may be more limited

>50%

of cancers are still diagnosed at later stages, when treatment options may be more limited

5-10 yrs

of silent biological change can precede clinical diagnosis in many chronic diseases

5-10 yrs

of silent biological change can precede clinical diagnosis in many chronic diseases

<1%

of the blood proteome is routinely measured by conventional clinical biomarker panels

<1%

of the blood proteome is routinely measured by conventional clinical biomarker panels


Detection gap in current clinical practice

Disease onset

Molecular changes

Proteome signals

Years before symptoms

Symptoms appear

Conventional diagnosis

Advanced stage

Limited intervention

Detection gap in current clinical practice

Disease onset

Molecular changes

Proteome signals

Years before symptoms

Symptoms appear

Conventional diagnosis

Advanced stage

Limited intervention

Detection gap in current clinical practice

Disease onset

Molecular changes

Proteome signals

Years before symptoms

Symptoms appear

Conventional diagnosis

Advanced stage

Limited intervention

PLATFORM

Turning population proteomics into early disease insight

Eliptica combines population-scale plasma proteomics, mass spectrometry and AI to discover early molecular signals of disease in blood, with the goal of translating them into future clinical tests for earlier detection and prevention.

01

Large deeply-phenotyped cohorts

Population-scale cohorts provide the biological diversity needed to detect early molecular changes linked to future disease.

01

Large deeply-phenotyped cohorts

Population-scale cohorts provide the biological diversity needed to detect early molecular changes linked to future disease.

02

Next-generation proteomics

Untargeted high-throughput mass spectrometry captures the proteome with isoform resolution and beyond the limits of narrow targeted panels.

02

Next-generation proteomics

Untargeted high-throughput mass spectrometry captures the proteome with isoform resolution and beyond the limits of narrow targeted panels.

03

Molecular AI models

AI models trained on human plasma identify disease-associated patterns in the blood proteome years before conventional clinical diagnosis.

03

Molecular AI models

AI models trained on human plasma identify disease-associated patterns in the blood proteome years before conventional clinical diagnosis.

04

Path to proprietary clinical tests

Prioritised indications are advanced towards assay development for validation, clinical utility and future early-detection or screening applications.

04

Path to proprietary clinical tests

Prioritised indications are advanced towards assay development for validation, clinical utility and future early-detection or screening applications.

Populations

Molecular data

AI models

Clinical tests

Populations

Molecular data

AI models

Clinical tests

Populations

Molecular data

AI models

Clinical tests

EVIDENCE AT SCALE

Population scale reveals disease
signals small studies miss

Early disease signals are subtle, distributed across many proteins and shaped by real-world variation. Population-scale proteomics provides the diversity and statistical power needed to detect patterns that small case-control studies often cannot resolve.

Conventional study

50-500
selected individuals

Population scale


500,000+
real-world
plasma proteomes

Conventional study

50-500
selected individuals

Population scale


500,000+
real-world
plasma proteomes

Detect subtle signals

More samples increase the power to identify weak, distributed proteomic patterns associated with future disease.

Detect subtle signals

More samples increase the power to identify weak, distributed proteomic patterns associated with future disease.

Capture human diversity

Large cohorts reflect real-wold differences in age, lifestyle, comorbidities and population structure that shape blood biology

Capture human diversity

Large cohorts reflect real-wold differences in age, lifestyle, comorbidities and population structure that shape blood biology

Build robust models

Scale helps models learn generalisable plasma biology rather than signatures that only work in small, selected cohorts.

Build robust models

Scale helps models learn generalisable plasma biology rather than signatures that only work in small, selected cohorts.

CLINICAL IMPACT

Earlier detection improves
health outcomes

Future blood-based tests will not only detect early molecular changes and improve treatment success but also enable closer monitoring,
further clinical assessment, and prevention.

01

Assess

Identify individuals who may benefit from follow-up before conventional diagnosis.

01

Assess

Identify individuals who may benefit from follow-up before conventional diagnosis.

01

Assess

Identify individuals who may benefit from follow-up before conventional diagnosis.

02

Stratify

Distinguish people with elevated molecular risk from those unlikely to need immediate action.

02

Stratify

Distinguish people with elevated molecular risk from those unlikely to need immediate action.

02

Stratify

Distinguish people with elevated molecular risk from those unlikely to need immediate action.

03

Intervene

Undertake timely therapeutical or surgical interventions

03

Intervene

Undertake timely therapeutical or surgical interventions

03

Intervene

Undertake timely therapeutical or surgical interventions

04

Monitor

Track disease-associated biology over time using repeat blood-based measurements.

04

Monitor

Track disease-associated biology over time using repeat blood-based measurements.

04

Monitor

Track disease-associated biology over time using repeat blood-based measurements.

Partner with us

Partner with us

We develop proprietary early-disease detection tests and partner with biopharma, clinical researchers, and cohorts to translate population-scale proteomics into clinical practice.

We develop proprietary early-disease detection tests and partner with biopharma, clinical researchers, and cohorts to translate population-scale proteomics into clinical practice.

info@eliptica.bio

The London Cancer Hub, Cotswold Road, London SM2 5NG

The London Cancer Hub,
Cotswold Road, London SM2 5NG